Table 4 shows the total RAS mutations detected in patient samples. Of the 53 patients, 25 patients (47%) had KRAS gene mutations detected in tumor tissue, 19 patients (35.8%) from plasma, and 19 patients (35.8%) from stool. No NRAS mutations were detected from tissue, plasma, and fecal samples. BRAF gene mutations were detected in tissue and plasma from six patients (11.3%) and in stool from three patients (5.7%). The gene discussed is KRAS; the disease is neoplasm.